BTK抑制剂tolebrutinib治疗多发性硬化症 (MS) ,显示出“有希望”的结果

2021-10-14 Allan MedSci原创

多发性硬化症(MS)是一种脱髓鞘性神经病变,患者脑或脊髓中的神经细胞表面的绝缘物质(即髓鞘)受到破坏,神经系统的信号转导受损,导致一系列可能发生的症状,影响患者的活动、心智、甚至精神状态。

多发性硬化症(MS)是一种脱髓鞘性神经病变,患者脑或脊髓中的神经细胞表面的绝缘物质(即髓鞘)受到破坏,神经系统的信号转导受损,导致一系列可能发生的症状,影响患者的活动、心智、甚至精神状态。这些症状可能包括复视、单侧视力受损、肌肉无力、感觉迟钝,或协调障碍。多发性硬化症的病情多变,患者的症状可能反复发作,也可能持续加剧。

多发性硬化症发生的三个重要特征包含出现中枢神经系统病灶、发炎反应,以及髓鞘破坏等。本疾病最常进犯视神经、脑干、基底核、脊髓,以及侧脑室周围的白质。

近日,法国制药公司赛诺菲公布了其研究性口服布鲁顿酪氨酸激酶 (BTK) 抑制剂tolebrutinib的新长期数据,结果显示,tolebrutinib在复发难治多发性硬化症 (MS) 患者中显示出“有希望的”安全性和有效性。

图1. 应用两步多重比较程序和建模后的估计剂量反应曲线

IIb期长期扩展研究 (LTS) 的结果表明,在治疗48周后,BTK抑制剂tolebrutinib降低了多发性硬化症 (MS) 疾病的活动度。

据赛诺菲称,根据“公开信息”,该数据使tolebrutinib成为唯一一种正在开发的用于MS的BTK抑制剂,该抑制剂已被证明可以直接调节小胶质细胞。

赛诺菲神经病学开发领域负责人Erik Wallström说:“了解脑渗透疗法减缓残疾积累的能力,有可能为难治性MS患者带来新的希望。近二十年来,赛诺菲一直坚定不移地努力加快为这些患者提供治疗方案”。

目前,tolebrutinib正在III期临床试验中进行评估,用于治疗MS、非复发性继发性进展性MS (nrSPMS) 和原发性进展性 MS (PPMS)。

 

原始出处:

http://www.pharmatimes.com/news/sanofis_btk_inhibitor_tolebrutinib_gains_promising_long-term_ms_data_1380733

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1890308, encodeId=a7b0189030802, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Jul 01 17:45:57 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983194, encodeId=410c19831948c, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Nov 16 20:45:57 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852778, encodeId=811a1852e78d7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Feb 02 02:45:57 CST 2022, time=2022-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297404, encodeId=eeb3129e40479, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Sat Oct 16 00:45:57 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539128, encodeId=c69b15391286c, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Sat Oct 16 00:45:57 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2022-07-01 jml2009
  2. [GetPortalCommentsPageByObjectIdResponse(id=1890308, encodeId=a7b0189030802, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Jul 01 17:45:57 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983194, encodeId=410c19831948c, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Nov 16 20:45:57 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852778, encodeId=811a1852e78d7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Feb 02 02:45:57 CST 2022, time=2022-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297404, encodeId=eeb3129e40479, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Sat Oct 16 00:45:57 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539128, encodeId=c69b15391286c, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Sat Oct 16 00:45:57 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1890308, encodeId=a7b0189030802, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Jul 01 17:45:57 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983194, encodeId=410c19831948c, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Nov 16 20:45:57 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852778, encodeId=811a1852e78d7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Feb 02 02:45:57 CST 2022, time=2022-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297404, encodeId=eeb3129e40479, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Sat Oct 16 00:45:57 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539128, encodeId=c69b15391286c, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Sat Oct 16 00:45:57 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2022-02-02 jklm09
  4. [GetPortalCommentsPageByObjectIdResponse(id=1890308, encodeId=a7b0189030802, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Jul 01 17:45:57 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983194, encodeId=410c19831948c, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Nov 16 20:45:57 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852778, encodeId=811a1852e78d7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Feb 02 02:45:57 CST 2022, time=2022-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297404, encodeId=eeb3129e40479, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Sat Oct 16 00:45:57 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539128, encodeId=c69b15391286c, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Sat Oct 16 00:45:57 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1890308, encodeId=a7b0189030802, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Jul 01 17:45:57 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983194, encodeId=410c19831948c, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Nov 16 20:45:57 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852778, encodeId=811a1852e78d7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Feb 02 02:45:57 CST 2022, time=2022-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297404, encodeId=eeb3129e40479, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Sat Oct 16 00:45:57 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539128, encodeId=c69b15391286c, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Sat Oct 16 00:45:57 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-10-16 fengting7

相关资讯

Neurology:复发缓解型多发性硬化,长期认知和运动障碍如何变化?

在临床实践中使用计算机化测试对认知进行监测,可能会发现认知变化的轨迹和有残疾进展风险的复发性缓解型多发性硬化症患者。

NNN:年轻成人超重/肥胖与多发性硬化症病因学中EBV感染方面的关系

由于肥胖影响细胞对感染的免疫反应,我们的目的是研究高体重指数(BMI)和高Epstein-Barr核抗原1 (EBNA-1)抗体水平是否与多发性硬化症(MS)风险有关。

JNER:多发性硬化症、帕金森病患者和健康对照者的实验室步态特征与日常生活步态特征

步态障碍疾病在神经系统疾病患者中非常常见,导致患者跌倒风险升高和生活质量降低。步态评估助于测试新干预措施的有效性。然尽管实验室步态评估提供了实验室条件下的步态信息,但它们可能无法反映日常活动中实际的功

Neurology:多发性硬化症患者结直肠癌生存率

在结直肠癌诊断后的早期,MS患者的总体和癌症特异性生存率较低。需要进一步研究以确定哪些因素可能导致这些糟糕的结局。

Nat Med:抗CD20治疗的多发性硬化症患者接种SARS-CoV-2 mRNA疫苗后的细胞和体液免疫应答

这些数据明确了接受aCD20治疗的患者接受SARS-CoV-2疫苗诱导的免疫反应的全景,并为协调mRNA疫苗诱导的人类免疫应答提供了重要见解。

Mult Scler:复发缓解型多发性硬化症患者应用单一SARS-COV-2疫苗后血清转换率降低

服用免疫抑制药物的病人优先接种SARS-COV-2疫苗。几种SARS-COV-2疫苗已在具有免疫能力的个人身上证明有效,强调体液免疫结果。但是,单剂疫苗对B细胞耗尽的患者的疗效尚不清楚。

拓展阅读

《新英格兰杂志》:CD40L抗体Frexalimab对多发性硬化症的作用

在此项使用Frexalimab治疗MS患者第2阶段试验中,CD40L抗体在治疗第12周,更有利于减少钆增强T1加权病变的新损伤数量。

JNNP: 复发缓解型多发性硬化症的造血干细胞移植——一项观察性队列研究

使用aHSCT治疗RRMS可使大多数患者摆脱疾病活动,且不良反应可接受。

Neurology:脊髓萎缩和脑顺磁环病变与多发性硬化症患者病情进展或复发活动的相关性

PIRA 与脊髓萎缩和 PRL 负担的增加有关,这种关联在 RRMS 患者中也很明显。

JNNP:多发性硬化症患者的心肺功能和磁共振成像神经炎症测量对海马体积的影响

较好的 CRF 可对多发性硬化症患者的海马完整性起到特殊的神经保护作用,但仅限于疾病的复发缓解阶段。

Annals of neurology:高水平的血管周围炎症和活动性脱髓鞘病变与快速进展性多发性硬化症病程有关

ALs 是疾病早期阶段的一个特征,在 PVI 水平较高的MS亚组换着中持续存在直到死亡。

Annals of neurology:多发性硬化皮层缺氧的时间模式及其对神经心理学和功能残疾的意义

fdNIRS 参数具有很高的再现性和可重复性,目前的结果已经证明多发性硬化症缺氧是一种慢性疾病,至少会持续一年。